Avita Medical (ASX: AVH) — Perfil da empresa, notícias e dados financeiros
Avita Medical specializes in regenerative medicine products to treat chronic wounds using innovative skin cell therapy.
Avita Medical
Avita Medical is a regenerative medicine company that develops and commercializes autologous cell therapies for acute wound care and skin restoration. Its primary focus is the development and commercialization of devices that allow healthcare professionals to prepare and administer Spray-On Skin Cells using a patient's own skin samples at the point of care. The company's therapeutic portfolio addresses acute wounds, full-thickness burns, surgical wounds, trauma, and dermatological conditions. By offering point-of-care cell delivery systems and complementary dermal and wound matrices, the company aims to expedite wound closure, minimize scar formation, reduce hospital stay durations, and improve overall patient recovery outcomes across global markets.
Resumo
Operações
Produtos e/ou serviços de Avita Medical
- Autologous Cell Suspension Systems: Medical devices that process a small skin sample at the point of care to create Spray-On Skin Cells, enabling rapid re-epithelialization and closure of severe burn injuries, full-thickness trauma, and surgical wounds.
- Biosynthetic Temporary Wound Matrices: Variable-porosity biosynthetic wound covers designed to protect acute burn and trauma sites, manage exudate, and maintain a moist healing environment until definitive skin grafting or natural tissue closure takes place.
- Collagen Dermal Matrices: Porous structural collagen matrices used to reconstruct dermal layers in complex full-thickness skin wounds, providing structural scaffold support to prepare tissue beds for definitive wound closure as early as day five post-injury.
- Clinical Development Programs: Conduct of multi-center clinical trials evaluating point-of-care autologous skin cell therapy for soft tissue reconstruction, repigmentation of stable vitiligo lesions, and expanded indications across major hospital networks.
- Surgical Burn Care Applications: Point-of-care therapeutic tools and protocols supplied to burn treatment centers and acute surgical units to reduce donor site requirements, lower infection risks, and shorten overall inpatient hospital stays.
- Global Commercial Operations: Distribution and direct sales of specialized acute wound care and skin restoration technologies to healthcare providers, trauma centers, and outpatient surgical centers across North America and key international markets.
equipe executiva do Avita Medical
- Cary G. VancePresident, CEO & Executive Director
- David O'TooleChief Financial Officer
- Nicole Linda KelseyChief Legal & Compliance Officer & Corporate Secretary
- Niraj DoshiSenior Vice President of Global Operations
- Katie BushSenior Vice President of Scientific & Medical Affairs
- Ben AtkinsVice President of Investor Relations & Corporate Communications
- Debbie GarnerSenior Vice President of Global Marketing & Strategy
- Rob JonesSenior Vice President of Human Resources
- Ron LagerquistSenior Vice President of Quality Assurance & Regulatory Affairs
- Robin VanDenburghSenior Vice President of U.S. Commercial Sales
Últimas notícias sobre a Avita Medical
AVITA Medical lifts guidance as Q2 revenue hits US$21.7M
AustraliaAVITA Medical reports revenue growth, narrowing losses
AustraliaAVITA Medical data shows faster wound healing results
AustraliaAVITA Medical secures $25.5M 10-year BARDA deal
AustraliaAVITA Medical posts 11% revenue growth in 2025
AustraliaAVITA Medical posts FY25 revenue growth, flags strong 2026 outlook
Australia
Comunicados recentes
O que a Avita Medical (AVH) comunicou ao mercado, do mais recente para o mais antigo.
- Statement of CDIs on issue - AVH
- Change of Director's Interest Notice - MT
- Notification regarding unquoted securities - AVH
- Notification of cessation of securities - AVH
- AVITA Highlights first UK Clinical Experience with RECELL GO
Principais indicadores financeiros
Resultados divulgados pela Avita Medical, em USD.
- Cap. de mercado
- 728,3 mi
- Receita (TTM)
- 75,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- -57.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 74,1 mi | -43,4 mi | -50,3 mi | |
| 64,3 mi | -56,6 mi | -61,8 mi | |
| 50,1 mi | -42,7 mi | -35,4 mi | |
| 34,4 mi | -27,5 mi | -39,2 mi |